Showing 5891-5900 of 9416 results for "".
- New Personalized Medicine Approach May Help Treat Even the Most Challenging Woundshttps://practicaldermatology.com/news/new-personalized-medicine-approach-to-wound-healing-may-help-treat-even-the-most-challenging-wounds/2458172/An experimental treatment that allows the reprogramming of blood cells to promote the healing process of cutaneous wound may be beneficial in healing challenging wounds. “We discovered a way to modify specific white blood cells – the macrophages – and make them capable o
- Sensus Healthcare Wins Technology Award from Greater Miami Chamber of Commercehttps://practicaldermatology.com/news/sensus-healthcare-wins-technology-award-from-greater-miami-chamber-of-commerce/2458174/Sensus Healthcare, Inc. was awarded the 2017 Technology Leader of the Year for the Disruptive Technology by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the company’s proprietary,
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- Tweaking TWEAK May Cool Inflammation in Pso and ADhttps://practicaldermatology.com/news/research-breakthrough-tweak-implicated-in-psoriasis-ad/2458178/New research pinpoints a common driver of skin inflammation in both psoriasis and atopic dermatitis. The findings, published in the May 22, 2017 issue of Nature Communications, showed that TWEAK, a protein related to
- SkinCeuticals Study Finds Antioxidants Protect Against Atmospheric Skin Aginghttps://practicaldermatology.com/news/skinceuticals-study-finds-antioxidants-protect-against-atmospheric-skin-aging/2458181/Exposure to ozone pollution zaps our collagen supply, according to new research from SkinCeuticals in partnership with Professor Giuseppe Valacchi from the University of Ferrara, Italy. After exposure to 0.8ppm ozone, collage
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- CVS Pharmacy's New Long Live Skin Campaign Aims to Increase Awareness of Skin Healthhttps://practicaldermatology.com/news/cvs-pharmacys-new-long-live-skin-campaign-aims-to-increase-awareness-of-skin-health/2458183/CVS Pharmacy, the retail division of CVS Health, is rolling out a new multi-platform Long Live Skin campaign to increase awareness about skin health, sun safety and proper skincare. The Long Live Skin Campaign kicks off today online&nbs
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- Study: Smiling May Not Make Us Appear Younger After Allhttps://practicaldermatology.com/news/study-smiling-may-not-make-us-appear-younger-after-all/2458186/Conventional wisdom suggests that smiling makes you appear younger, but researchers at Ben-Gurion University of the Negev in Israel beg to differ. People who smile are actually perceived as older than those with a deadpan or surprised expression, according
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to